Gil Fridberg

Jaffa, TA, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: April 04, 2026

Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes.

Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes.

Journal: Cancers

Published: January 13, 2026

Sequential therapy with allogeneic HCT in patients aged ≥70 years with active AML: a single-center retrospective analysis.

Sequential therapy with allogeneic HCT in patients aged ≥70 years with active AML: a single-center retrospective analysis.

Journal: Haematologica

Published: November 07, 2025

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

Journal: Haematologica

Published: August 19, 2025

Research Letter: Immune Cell Profiling in Lymphoma Patients Treated With CAR-T Cell Therapy and Nivolumab.

Research Letter: Immune Cell Profiling in Lymphoma Patients Treated With CAR-T Cell Therapy and Nivolumab.

Journal: Transplantation and cellular therapy

Published: July 20, 2025

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study.

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study.

Journal: Hematological oncology

Published: May 22, 2025

The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes-A Single-Center Longitudinal Cohort Analysis.

The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes-A Single-Center Longitudinal Cohort Analysis.

Journal: Cancers

Published: August 03, 2024

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

Journal: Transplantation and cellular therapy

Published: July 31, 2024

The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy.

The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy.

Journal: Cancers

Published: October 29, 2023

Lesion location impact on functional recovery of the hemiparetic upper limb.

Lesion location impact on functional recovery of the hemiparetic upper limb.

Journal: PloS one

Published: July 18, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026